A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer

Objectives: Src family kinases (SFKs) are expressed in non-small cell lung cancer (NSCLC) and may be involved in tumor growth and metastases. Inhibition of SFK may also enhance radiation. The purpose of this study was to evaluate if a maximum dose of 100 mg of dasatinib could be safely administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurshid, Humera, Dipetrillo, Thomas, Ng, Thomas, Mantripragada, Kalyan, Birnbaum, Ariel, Berz, David, Radie-Keane, Kathy, Perez, Kimberly, Constantinou, Maria, Luppe, Denise, Schumacher, Andrew, Leonard, Kara, Safran, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364482/
https://www.ncbi.nlm.nih.gov/pubmed/22666662
http://dx.doi.org/10.3389/fonc.2012.00056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364482/
https://www.ncbi.nlm.nih.gov/pubmed/22666662
http://dx.doi.org/10.3389/fonc.2012.00056

Ejemplares similares